Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159794 | 0.92 | TGM2 (0.54) | TGM2FAAHMGLLKMT2APTGS2 | |
| Hydrochloric Acid SCHEMBL11260539 | 0.90 | TGM2 (0.53) | TGM2FAAHMGLLKMT2APTGS2 | |
| Bicarbonate SCHEMBL5659085 | 0.87 | TGM2 (0.54) | TGM2FAAHMGLLKMT2APTGS2 | |
| Nitric Acid SCHEMBL2075198 | 0.85 | LMNA (0.48) | LMNAMAPTALDH1A1KMT2ACA1 | |
| Nitric Acid SCHEMBL9982936 | 0.81 | LMNA (0.49) | TGM2LMNAMAPTALDH1A1KMT2A | |
| Nitric Acid SCHEMBL2073717 | 0.80 | KMT2A (0.50) | MAPTALDH1A1KMT2ACA1CA2 | |
| Nitric Acid SCHEMBL2852035 | 0.80 | PEPD (0.52) | LMNAGAAMAPTALDH1A1KMT2A | |
| Nitric Acid SCHEMBL4613840 | 0.78 | ALDH1A1 (0.53) | TGM2LMNAGAAMAPTALDH1A1 | |
| Nitric Acid SCHEMBL2544082 | 0.78 | NPC1 (0.53) | LMNAGAAMAPTALDH1A1KMT2A | |
| Nitric Acid SCHEMBL3860512 | 0.78 | KMT2A (0.59) | TGM2LMNAGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621952-A1 | METHOD FOR THE PRODUCTION OF PHENYLGUANIDINES OR THE SALTS THEREOF | AlzChem Trostberg GmbH (DE) | 2020-03-18 | — | — | EP | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| CN-1711258-A | Pyrimidine compounds | CYCLACEL LTD (GB) | 2005-12-21 | — | — | CN | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | TGM2 2385/4885ALDH3A1 1822/4885LMNA 2306/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | TGM2 2385/4885ALDH3A1 1822/4885LMNA 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.